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Abstract: Background: High physiological 16α-[18F]-fluoro-17β-estradiol ([18F]-FES) uptake in the
abdomen is a limitation of this positron emission tomography (PET) tracer. Therefore, we investigated
the effect of food intake prior to PET acquisition on abdominal background activity in [18F]-FES-PET
scans. Methods: Breast cancer patients referred for [18F]-FES-PET were included. Three groups
were designed: (1) patients who consumed a chocolate bar (fatty meal) between tracer injection
and imaging (n = 20), (2) patients who fasted before imaging (n = 20), and (3) patients without diet
restrictions (control group, n = 20). We compared the physiological [18F]-FES uptake, expressed as
mean standardized uptake value (SUVmean), in the abdomen between groups. Results: A significant
difference in [18F]-FES uptake in the gall bladder and stomach lumen was observed between groups,
with the lowest values for the chocolate group and highest for the fasting group (p = 0.015 and
p = 0.011, respectively). Post hoc analysis showed significant differences in the SUVmean of these
organs between the chocolate and fasting groups, but not between the chocolate and control groups.
Conclusion: This exploratory study showed that, compared to fasting, eating chocolate decreases
physiological gall bladder and stomach [18F]-FES uptake; further reduction through a normal diet
was not seen. A prospective study is warranted to confirm this finding.
Keywords: FES-PET; breast cancer; abdominal distribution; fasting; chocolate
1. Introduction
Information about estrogen receptor (ER) expression in breast cancer (BC) is essential, because it
can guide important therapy decisions. ER-positive lesions are found in about 70% of BCs, and these
tumors are likely to respond to endocrine treatment [1]. Nowadays, the gold standard for determining
the ER status is immunohistochemistry of biopsy samples. However, in clinical practice, a biopsy is
not always feasible or may lead to sample errors. When diagnostic dilemmas cannot be solved with
conventional imaging methods, molecular imaging with 16α-[18F]-fluoro-17β-estradiol ([18F]-FES)
positron emission tomography (PET) may be used to obtain, in a non-invasive way, whole-body
information about ER expression of all tumor lesions within the body. This imaging technique may
improve diagnostic understanding and may help in therapy decision-making [2,3]. However, there are
limitations in the use of this molecular imaging technique, such as high physiological [18F]-FES uptake
in the gall bladder and bile ducts, and excretion into the gastrointestinal tract. [18F]-FES is rapidly
metabolized in the liver and excreted by the gall bladder and bile ducts into the gastrointestinal tract,
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resulting in high background activity in these organs, which can hamper interpretation of [18F]-FES-PET
in the abdominal region. This limitation of [18F]-FES-PET is especially important in patients with
ovarian tumors, which most commonly develop intra-abdominal metastases [4].
Methods to enhance the contrast between ER-positive tumor lesions and physiological uptake
could aid the accurate visualization of abdominal metastases. One method could be to increase the
hepatobiliary clearance rate of the tracer. This might potentially be achieved by stimulating gall
bladder contraction with a (fatty) meal around the time of tracer injection, which would result in faster
passage of the tracer from the liver to duodenum. This method is commonly used in nuclear medicine
for myocardial perfusion imaging [5–9]. Several high-fat meals have been investigated in the field
of myocardial perfusion, such as milkshakes [6], full-fat milk [7,8], and chocolate [9]. Our hospital
uses chocolate as a fatty meal between injection and myocardial perfusion imaging, and therefore
chocolate was selected for this study as well. Chocolate has also been used as a high-lipid food in
studies investigating cholecystography [10].
On the other hand, fasting (at least 4 h before imaging) has also been suggested to reduce bowel
accumulation due to reduced elimination of [18F]-FES from the gall bladder [11]. Nowadays, different
patient preparation instructions are used for [18F]-FES-PET imaging, such as fasting, oral hydration
with water, and non-fasting [11–13]. The first recommendation paper about [18F]-FES-PET concluded
that no specific patient preparation instructions are necessary, except when the PET scan is acquired in
combination with a diagnostic (contrast-enhanced) computed tomography (CT)-scan [14].
The aim of this single-center exploratory study is to assess the effect of food intake prior to PET
acquisition (a fatty meal (chocolate) between tracer injection and imaging, a period of fasting prior to
imaging, and no diet restrictions) on abdominal background [18F]-FES activity in patients with BC.
We hypothesized that the administration of chocolate before [18F]-FES-PET imaging would lead to
faster excretion, resulting in less-disturbing physiological [18F]-FES uptake in the gall bladder and
upper gastrointestinal tract, whereas fasting would increase background tracer uptake in these organs.
2. Materials and Methods
2.1. Patients
We included BC patients who have been referred for [18F]-FES-PET by their treating physician as
part of routine clinical practice in the University Medical Center Groningen (UMCG) from February
2012 till August 2019. [18F]-FES-PET was requested because of a clinical dilemma, when standard
workup was inconclusive. Patients were divided into three groups based on their food intake before
the PET scan:
(1) Chocolate group (used as a fatty meal), which included 20 prospectively collected, consecutive
patients who ate a chocolate bar directly after tracer injection and before [18F]-FES-PET imaging.
The weight of the milk chocolate bar was 47 g, and contained 248 kcal (1036 kJ). The amount of
fat was 14 g, or 20% of total daily fat intake.
(2) Fasting group (n = 20), which included retrospectively collected patients without any food intake
at least 4–6 h prior to the [18F]-FES-PET scan, and patients who were instructed to fast due to
combined contrast-enhanced CT-scan.
(3) Control group without any diet restrictions prior to tracer injection (which was our standard
patient preparation; n = 20). This group was also retrospectively selected from a larger database.
Patients were excluded when [18F]-FES-PET was performed for research purposes, if they had
an intolerance to or refused to eat chocolate, and if liver metastases were present to avoid overlap
of tracer uptake in tumors with the gall bladder and/or bile ducts. Both the fasting and control
groups were matched based on sex, age, weight, menopausal status (postmenopausal status was
defined as age ≥60 years, age <60 years and amenorrhea for >12 months without oral contraceptives,
or chemical/surgical ovarian function suppression), and use of ER-antagonists (treatment was stopped
at least 5 weeks before the PET scan), using the chocolate group as reference.
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2.2. Study Design
This was a single-center exploratory study performed at the UMCG, The Netherlands. The Medical
Ethics Committee of the UMCG has reviewed the protocol and decided that this type of research was
beyond the scope of the Medical Research Involving Human Subjects Act (WMO) (METc 2018/2017).
Patients in the chocolate group did provide verbal informed consent for consuming chocolate prior to the
scan. The primary endpoint of the study was the physiological [18F]-FES uptake in the gastrointestinal
tract (liver, gall bladder or bile ducts, small and large bowel), expressed as mean standardized uptake
value (SUVmean).
2.3. [18F]-FES-PET
Patients received ~200 MBq of [18F]-FES intravenously. Whole-body (head to mid-thigh) PET/CT
was performed 60 min after tracer injection using a Siemens Biograph (Siemens Healthineers, Knoxville,
TN, USA) 40- or 64-slice mCT with a PET emission acquisition time of 3 min per bed position. Low-dose
CT was acquired for attenuation and scatter correction. Reconstructions of the scan and quantification
were performed according to the European Association of Nuclear Medicine (EANM, Vienna, Austria)
guidelines for 18F imaging and the EANM Research Limited (EARL, Vienna, Austria) criteria [15].
All quantifications were performed on EARL reconstructed images with a 2 mm reconstructed
spatial resolution.
2.4. [18F]-FES-PET Data Analysis
We used syngo.via VB30 imaging software (Siemens Healthineers, Knoxville, TN, USA) for
quantitative measurements of tracer uptake in various abdominal organs. All PET images were
evaluated for physiological [18F]-FES uptake by drawing volumes of interest (VOIs) in the lumen and
wall of various parts of the gastrointestinal tract (the colon was dived into: the cecum, the ascending,
transverse, and descending sections, and sigmoid, and rectum), liver, gall bladder, and the blood pool
as reference. The median [18F]-FES uptake and interquartile range per organ and per group were
reported. Tracer uptake in the liver was determined by placing 3 spherical VOIs with a diameter
between 2.5 and 3.5 cm (segment 2, 5/8 and 6). The average tracer uptake in these VOIs was reported.
Two measurements were performed for the stomach (wall and lumen) and the blood pool (aortic
arch and descending thoracic aorta). For patients who underwent a gall bladder excision in the past,
[18F]-FES uptake was determined in the bile ducts instead of the gall bladder. All measurements were
performed by a trained observer (KG; unaware of the patient grouping), and doublechecked by a
second trained observer (JB), all under supervision of an experienced nuclear medicine physician (AG).
2.5. Statistical Analysis
Descriptive analysis of [18F]-FES uptake per organ and per group was performed. When the
results were normally distributed, continuous variables were expressed as mean ± standard deviation
(SD); otherwise, median and interquartile range were noted. Categorical variables were expressed as
numbers (percentage) and analyzed with the Chi-square test. Continuous and normally distributed
variables were analyzed with the One-Way ANOVA test. The Kruskal–Wallis test was used for
comparisons between differences in physiological [18F]-FES uptake between groups, because the
groups were unrelated and lacked normality (normal distribution of the data could not be proven with
the Shapiro–Wilk test, Levene’s test and Q–Q plot). To test the significance of the differences between
individual groups and correct for multiple comparisons, we used the Dunn–Bonferroni post hoc
correction method. Statistical significance was defined by a probability (p) value ≤ 0.05. Analyses were
performed using IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, NY, USA).
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3. Results
3.1. Patients
Patient characteristics are summarized in Table 1. The majority of patients (78%) had metastatic
disease. There were no statistically significant differences in age, weight, BMI, and menopausal status
between the three groups. All patients who used ER-antagonists discontinued this treatment >5 weeks
before [18F]-FES-PET imaging. All patients who received a chocolate bar ate the whole bar, except for
one patient who ate 5/6 of the bar. Since the control group without diet restriction was established
retrospectively, no information was available about their food consumption prior to the PET scan.
However, based on the information that the tracer injection is always administered during the early
afternoon, it is likely that patients had had lunch before the scan. Similarly, the exact number of
fast hours is unknown in the fasting group. The majority of patients (16/20) needed to fast for at
least 4–6 h prior to the [18F]-FES-PET scan, and 4 patients were instructed to fast due to combined
contrast-enhanced CT-scan. Of these 4 patients, three patients probably had to fast for at least 3.5 h,
and one patient for at least 2.5 h.
Table 1. Baseline characteristics of breast cancer patients (n = 60).






(n = 20) p-Value
Age, years 68 (30–83) 69 (40–77) 66 (30–74) 69 (40–83) 0.33
Weight, kg 76 ± 15 76 ± 14 77 ± 19 73 ± 12 0.72
Height, cm 167 ± 7 166 ± 8 169 ± 6 166 ± 6 0.50
BMI, kg/m2 28 ± 5 28 ± 4 27 ± 6 27 ± 4 0.84
Menopausal status 0.87
Peri/premenopausal 8 (13) 2 (10) 3 (15) 3 (15)
Postmenopausal 52 (87) 18 (90) 17 (85) 17 (85)
Cholecystectomy 7 (12) 5 (25) 2 (10) -
Treatment [18F]-FES-PET
Aromatase inhibitor 19 (32) 5 (25) 7 (35) 7 (35)
Chemotherapy 3 (5) 1 (5) 1 (5) 1 (5)
None 38 (63) 14 (70) 12 (60) 12 (60)
[18F]-FES-PET result ¶
Positive 38 (63) 13 (65) 11 (55) 14 (70)
Negative 22 (37) 7 (35) 9 (45) 6 (30)
Stage
Adjuvant 13 (22) 5 (25) 1 (5) 7 (35)
Metastatic † 47 (78) 15 (75) 19 (95) 13 (65)
Values are presented as median (range), mean ± standard deviation (SD), or total number (%). ¶ Positive result was
defined as clearly visible tumor tracer uptake above background activity; negative result was defined as absence of
visual tracer uptake at the location of a metastasis detected by conventional imaging. † Including oligometastases.
3.2. Physiological [18F]-FES Uptake
Table 2 and Figure 1 summarize the physiological [18F]-FES uptake in the abdomen for the three
groups. On visual analysis, no clear changes in physiological uptake could be seen between the three
food intake protocols (Figure 1).
Diagnostics 2020, 10, 756 5 of 11
Table 2. Physiological [18F]-FES uptake (SUVmean) per food intake protocol and per organ.




























































































Values are presented as median and interquartile range. * In 2 out of 60 patients (one of the chocolate group and
one of the control group) it was not possible to measure physiological [18F]-FES uptake in the rectum, due to rectal
surgery for rectal cancer and rectal metastases from lobular carcinoma.
Quantitative analysis revealed that physiological [18F]-FES uptake in the gall bladder/bile ducts
and lumen of the stomach was significantly different between the groups, with the lowest tracer uptake
in the chocolate group and highest uptake in the fasting group (see Figure 2). After consumption
of chocolate, the median [18F]-FES uptake (SUVmean) in the gall bladder was 71 (interquartile range
38–91), compared to 85 (62–128) for the control group, and 102 (68–140) for the fasting group (p = 0.015).
Figure 3 shows the clear visual difference in gall bladder [18F]-FES uptake between the chocolate diet
and the standard protocol without food restrictions, within the same patient. A post hoc analysis was
performed to see which pairs of groups differ significantly in physiological [18F]-FES uptake (SUVmean)
in the gall bladder/bile ducts. The tracer uptake in the gall bladder/bile ducts was significantly lower
in patients who ate a chocolate bar compared to patients who were instructed to fast (p = 0.013).
Comparison of the control and the fasting groups, or the control and the chocolate groups, did not
show significant differences in gall bladder uptake (p = 0.92 and p = 0.20, respectively). Subanalysis of
patients whose gall bladder was still in situ (excluding patients with cholecystectomy) showed a similar,
but more pronounced, [18F]-FES uptake pattern in the gall bladder, with the lowest tracer uptake in
the chocolate group and highest uptake in the fasting group (69 (26–87), compared to 85 (62–128),
and 108 (78–143), respectively (p = 0.007)). A post hoc analysis of differences in gall bladder [18F]-FES
uptake showed the same statistically significant effect for the chocolate group compared to the fasting
group (p = 0.005). In a subanalysis of patients without gall bladder (n = 7), no significant differences in
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[18F]-FES uptake in the bile ducts between the groups were observed (chocolate diet (n = 5): 72 (48–97)
versus fasting protocol (n = 2): 56 (54–56); p = 0.245)).
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Figure 1. [18F]-FES-PET scans of breast cancer patients showing visual enhanced physiological [18F]-FES
uptake in all protocols: (a) chocolate, (b) fasting, and (c) control group.
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food intake protocols.
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4. Discussion
In this exploratory study, we assessed the effect of food intake before the [18F]-FES-PET scan
(a fatty meal (chocolate), fasting, and no diet restrictions) on abdominal background [18F]-FES activity
in patients with BC.
This is the first study focusing on different patient preparation protocols for [18F]-FES-PET studies,
with a particular focus on the dietary instructions before imaging. The use of standardized patient
preparation protocols for [18F]-FES-PET reduces factors that can influence [18F]-FES uptake. Given the
recent FDA approval of [18F]-FES, the optimization and standardization of dietary instructions prior to
PET acquisition are highly needed.
Our results showed differences in background [18F]-FES activity in the upper abdomen between
the food intake protocols. The chocolate group demonstrated significantly decreased [18F]-FES uptake
in the gall bladder and stomach lumen compared to the fasting group, probably due to a faster excretion
from these organs and thereby increased motility through the upper gastrointestinal tract. This result
is strengthened by the fact that this effect was only seen in those patients with gall bladder and was
not observed in patients with resected gall bladder. The slight decrease in tracer uptake in gall bladder
and stomach was indeed accompanied by a nonsignificant increase in tracer uptake in the small bowel.
This nonsignificant trend towards a higher uptake in the small bowel after fatty preparation diet can
also hamper the detection of tumor in this region. Based on this finding, we cannot conclude that the
chocolate diet is superior to the fasting protocol. Further research and additional groups with other
patient preparation protocols might possibly help to decrease the tracer uptake in the small bowel as
well. One suggestion could be to increase the time interval between tracer injection and the start of the
scan. In the present study, all scans were performed 60 min after tracer administration. Scanning at
later time points is feasible since we know that [18F]-FES uptake in ER-expressing tumors remains
stable till at least 120 min after tracer injection [16]. Based on our findings, one could speculate that
laxative agents directly after [18F]-FES injection and before [18F]-FES-PET acquisition can maybe also
further reduce the physiological [18F]-FES uptake in the upper abdomen, including the small bowel.
Different bowel-cleansing methods (including laxatives and dietary restrictions) were investigated in
a previous [18F]-fluorodeoxyglucose ([18F]-FDG)-PET imaging study [17]. They found an increased
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number of false-positive [18F]-FDG-PET scans in the group with laxatives, for example, because of
smooth muscle activity. In contrast to [18F]-FDG, muscle activity does not affect the physiological
[18F]-FES uptake. Furthermore, no statistical differences in physiological [18F]-FES uptake between
the food intake protocols were seen in the other gastrointestinal tract regions, in particular, no trend
towards a higher uptake in the large colon. Diffuse uptake of [18F]-FES in the colon and the large
colon volume may be responsible for this lack of statistical significance. Increasing the time interval
may possibly also lead to larger differences in physiological tracer uptake in the lower abdomen.
These additional methods (increasing the time interval and using laxatives) can be added to a future
clinical prospective trial.
Our quantitative results suggest that a chocolate diet might be helpful in less-disturbing
background [18F]-FES activity in the gall bladder and stomach. In addition, in one patient we
found a visual difference in physiological gall bladder [18F]-FES uptake between the chocolate diet
and no dietary restriction protocol. This was achieved by stimulating gall bladder contraction with
a fatty meal around the time of tracer injection, which would increase the hepatobiliary clearance
rate of the [18F]-FES tracer. It therefore seems likely that this food intake protocol may increase the
contrast between background [18F]-FES activity and tracer uptake at tumor sites in the gall bladder and
stomach. However, if this finding actually appears in patients with gastrointestinal tract metastasis is
still unknown. In the present study, patients with liver metastases were excluded, and none of the
patients had metastatic BC to the gastrointestinal tract, except for one patient who had rectal metastases
from lobular carcinoma. Therefore, the [18F]-FES-PET diagnostic accuracy between the groups needs
to be further investigated in patients with ER-positive abdominal metastases, using visual inspection
and quantitative analysis. A prospective study, in which the actual diet of the control and fasting
groups is included, should assess if the visualization of upper abdominal metastases will improve by
using different food intake protocols, resulting in improved detection of ER-positive metastatic cancer.
Foremost, it is important to bear in mind that a fasting protocol is less patient-friendly compared to
the other two protocols. Ultimately, future studies may be helpful to formulate advice about the best
patient preparation instructions.
Gastrointestinal tract involvement is typically found in patients with lobular metastatic BC [18,19].
A previous case report presented [18F]-FES-PET findings of a patient with metastatic lobular BC with
gastric linitis plastic [20], in which the chocolate protocol may possibly have facilitated tumor detection
because of a nonsignificant trend towards lower uptake in the stomach wall. Indeed, metastatic BC to
the stomach is rare, and the majority of these patients have ER-positive disease, but ER expression is
not only present in BC, but in other (gynecological) tumors as well, such as uterine tumors, ovarian,
endometrial, and gastric cancer [4,21–28]. For ovarian cancer, detection of abdominal metastases by
[18F]-FES-PET could be important. A previous [18F]-FES-PET study including ovarian tumors showed
that most lesions were intra-abdominal metastases [4]. Detection of these lesions was sometimes
hampered by high physiological [18F]-FES uptake.
The main reasons for using chocolate as the fatty meal in our study was its easy availability,
as well as the simplicity of its consumption. Furthermore, eating chocolate is also used regularly in the
preparation of myocardial perfusion scans and thus can be easily implemented. Milk chocolate was
also used in a previous imaging study as a fatty meal to stimulate gall bladder contraction with good
results [10]. However, compared to milk chocolate, dark chocolate has higher percentages of fat and
may show even more pronounced results.
This study has several limitations, including the retrospective design of the control and fasting
groups, and consequently the lack of information about the diet of patients in the control group, as well
as the exact number of fast hours in the fasting group. This study did not allow us to clarify whether
the effect of chocolate was related to the fat content or caloric value of the meal, so the exact mechanism
by which a chocolate diet decreases [18F]-FES uptake in stomach and gall bladder could not be clearly
defined. The strengths of this study are the sample size of the three groups, the prospective design of
the chocolate group, the comparison of multiple food intake protocols, and using matched groups with
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limited confounding factors that could affect [18F]-FES uptake. Furthermore, all scans were performed
with standardized acquisition and reconstruction protocols in the same institution.
In conclusion, in this exploratory study we showed that, compared to fasting, eating chocolate
decreases physiological [18F]-FES uptake in the gall bladder and stomach. This might be caused
by accelerated passage of the tracer. Eating a fatty meal (chocolate) does not significantly decrease
[18F]-FES uptake further compared to a normal diet. A prospective study, in which patients with
abdominal metastases are included, is warranted to confirm this finding.
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